SCHEMBL1358074

SCHEMBL1358074

CCCCCCOC(C)(CO)OCCCCCC

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
THRB P10828 1/20 0.45
HTT P42858 1/20 0.45
MAPT P10636 1/20 0.45
LMNA P02545 2/20 0.40
TSHR P16473 2/20 0.40
ALDH1A1 P00352 1/20 0.40
HSD17B10 Q99714 1/20 0.40
USP2 O75604 1/20 0.39
NR5A1 Q13285 1/20 0.39
LPAR3 Q9UBY5 6/20 0.39
LPAR2 Q9HBW0 5/20 0.39
LPAR1 Q92633 2/20 0.39
NAAA Q02083 1/20 0.39
CES2 O00748 2/20 0.38
CES1 P23141 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6021113 1.00 MEN1 (0.45) MEN1KMT2ATHRBHTTMAPT
SCHEMBL22971752 0.98 MEN1 (0.41) MEN1KMT2ATHRBHTTMAPT
SCHEMBL22960180 0.93 TSHR (0.44) MEN1KMT2ATHRBHTTMAPT
SCHEMBL8420927 0.86 TSHR (0.39) MEN1KMT2ATHRBHTTMAPT
SCHEMBL19098226 0.82 MEN1 (0.45) MEN1KMT2ATHRBHTTMAPT
SCHEMBL19098580 0.82 MEN1 (0.45) MEN1KMT2ATHRBHTTMAPT
SCHEMBL14211509 0.82 MEN1 (0.45) MEN1KMT2ATHRBHTTMAPT
SCHEMBL12257499 0.81 LPAR3 (0.41) MEN1KMT2ATHRBHTTMAPT
SCHEMBL12257497 0.81 LPAR3 (0.41) MEN1KMT2ATHRBHTTMAPT
SCHEMBL1839694 0.80 MEN1 (0.43) MEN1KMT2ATHRBHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4010327-B1 ACID-LABILE SURFACTANTS PROMEGA CORP (US) 2024-10-02 EP disclosed
US-11939311-B2 Acid-labile surfactants PROMEGA CORPORATION (US) 2024-03-26 US disclosed
EP-4010327-A1 ACID-LABILE SURFACTANTS Promega Corporation (US) 2022-06-15 EP disclosed
US-20210040058-A1 ACID-LABILE SURFACTANTS PROMEGA CORPORATION 2021-02-11 US disclosed
WO-2021026316-A1 ACID-LABILE SURFACTANTS PROMEGA CORPORATION (US) 2021-02-11 WO disclosed
WO-2021026316-A1 ACID-LABILE SURFACTANTS PROMEGA CORPORATION (US) 2021-02-11 WO disclosed
US-20210040058-A1 ACID-LABILE SURFACTANTS PROMEGA CORPORATION 2021-02-11 US disclosed
US-8445223-B2 Anionic acid-labile surfactants and methods of use PROTEA BIOSCIENCES, INC. (US) 2013-05-21 US disclosed
US-8445223-B2 Anionic acid-labile surfactants and methods of use PROTEA BIOSCIENCES, INC. (US) 2013-05-21 US disclosed
US-8445223-B2 Anionic acid-labile surfactants and methods of use PROTEA BIOSCIENCES, INC. (US) 2013-05-21 US disclosed
US-8232423-B2 Anionic acid-labile surfactants and methods of use PROTEA BIOSCIENCES, INC. (US) 2012-07-31 US disclosed
US-20110282096-A1 ANIONIC ACID-LABILE SURFACTANTS AND METHODS OF USE PROTEA BIOSCIENCES, INC. 2011-11-17 US disclosed
US-20110282096-A1 ANIONIC ACID-LABILE SURFACTANTS AND METHODS OF USE PROTEA BIOSCIENCES, INC. 2011-11-17 US disclosed
US-20110282096-A1 ANIONIC ACID-LABILE SURFACTANTS AND METHODS OF USE PROTEA BIOSCIENCES, INC. 2011-11-17 US disclosed
US-8013179-B2 Anionic acid-labile surfactants and methods of use PROTEA BIOSCIENCES, INC. (US) 2011-09-06 US disclosed
US-8013179-B2 Anionic acid-labile surfactants and methods of use PROTEA BIOSCIENCES, INC. (US) 2011-09-06 US disclosed
US-8013179-B2 Anionic acid-labile surfactants and methods of use PROTEA BIOSCIENCES, INC. (US) 2011-09-06 US disclosed
US-20090292136-A1 Anionic acid-labile surfactants and methods of use SUMMIT RESOURCES, INC. 2009-11-26 US disclosed
US-20090292136-A1 Anionic acid-labile surfactants and methods of use SUMMIT RESOURCES, INC. 2009-11-26 US disclosed
US-20090292136-A1 Anionic acid-labile surfactants and methods of use SUMMIT RESOURCES, INC. 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110282096-A1 ANIONIC ACID-LABILE SURFACTANTS AND METHODS OF USE H1-0, H1-2, H1-3 MEN1 2852/4885KMT2A 4108/4885THRB 4110/4885
US-20090292136-A1 Anionic acid-labile surfactants and methods of use H1-0, H1-2, H1-3 MEN1 1404/4885KMT2A 2621/4885THRB 3676/4885
US-20210040058-A1 ACID-LABILE SURFACTANTS SMURF1, S100A6, SPAST MEN1 3678/4885KMT2A 4671/4885THRB 3938/4885
US-11939311-B2 Acid-labile surfactants SMURF1, S100A6, SPAST MEN1 3678/4885KMT2A 4671/4885THRB 3938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.